Upregulated RAI2 inhibits migration and invasion of endometrial cancer cell lines HEC-1-A and KLE

doi:10.16352/j.issn.1001-6325.2023.10.1537

Abstract

Abstract: Objective To investigate the effect of upregulation of retinoic acid-induced 2 (RAI2) expression on the migration and invasion of endometrial cancer cells. Methods The endometrial cancer cell lines HEC-1-A and KLE were used for this study. Scratch assay and Transwell chamber assay were used to evaluate the migration and invasion of endometrial cancer cells. Immunofluorescence and Western blot were used to detect the expression of RAI2, E-cadherin, and vimentin. Results The upregulation of RAI2 expression in HEC-1-A and KLE cells significantly reduced migration and invasion ability (P＜0.05). The expression levels of RAI2 and E-cadherin were increased, while the vimentin expression level was decreased (P＜0.05). Conclusions Upregulation of RAI2 expression may inhibit endometrial cancer cell migration and invasion through epithelial-mesenchymal transition.

Key words: endometrial cancer, retinoic acid-induced 2(RAI2), migration, invasion

CLC Number:

R711.7

NIE Dan, WANG Chunyan, LI Zhengyu. Upregulated RAI2 inhibits migration and invasion of endometrial cancer cell lines HEC-1-A and KLE[J]. Basic & Clinical Medicine, 2023, 43(10): 1537-1541.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.10.1537

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I10/1537

References

[1]Jonk LJ, de Jonge ME, Vervaart JM, et al. Isolation and developmental expression of retinoic-acid-induced genes[J]. Dev Biol, 1994,161:604-614.
[2]Werner S, Brors B, Eick J, et al. Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic acid-induced 2 [J]. Cancer Discov, 2015,5:506-519.
[3]Besler K, Węglarz A, Keller L, et al. Expression patterns and corepressor function of retinoic acid-induced 2 in prostate cancer[J]. Clin Chem, 2022,68:973-983.
[4]Zhang W, Kong L, Zhu H, et al. Retinoic acid-induced 2 (RAI2) is a novel antagonist of Wnt/β-Catenin signaling pathway and potential biomarker of chemosensitivity in colorectal cancer[J]. Front Oncol, 2022,12:805290. doi: 10.3389/fonc.2022.805290.
[5]Walpole SM, Hiriyana KT, Nicolaou A, et al. Identification and characterization of the human homologue (RAI2) of a mouse retinoic acid-induced gene in Xp22[J]. Genomics, 1999,55:275-283.
[6]Esposito M, Kang Y. RAI2: linking retinoic acid signaling with metastasis suppression[J]. Cancer Discov, 2015,5:466-468.
[7]Yan W, Wu K, Herman JG, et al. Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer[J]. Clin Epigenetics, 2018,10:69. doi: 10.1186/s13148-018-0501-4.
[8]Nishikawa S, Uemoto Y, Kim TS, et al. Low RAI2 expression is a marker of poor prognosis in breast cancer[J]. Breast Cancer Res Treat, 2021,187:81-93.
[9]Yang C, Mou Z, Zhang Z, et al. Circular RNA RBPMS inhibits bladder cancer progression via miR-330-3p/RAI2 regulation[J]. Mol Ther Nucleic Acids, 2021,23:872-886.
[10]Huang M, Ding J, Wu X, et al. EZH2 affects malignant progression and DNA damage repair of lung adenocarcinoma cells by regulating RAI2 expression[J]. Mutat Res, 2022,825:111792. doi: 10.1016/j.mrfmmm.2022.111792.
[11]Yu Y, Lu X, Yan Y, et al. The lncRNA KIF9-AS1 accelerates hepatocellular carcinoma growth by recruiting DNMT1 to promote RAI2 DNA methylation[J]. J Oncol, 2022,2022:3888798. doi: 10.1155/2022/3888798.
[12]Gelissen JH, Huang GS. Intersections of endocrine pathways and the epithelial mesenchymal transition in endometrial cancer[J]. Front Oncol,2022,12: 914405. doi: 10.3389/fonc.2022.914405.

[1]	YANG Tingting, HUANG Jie, GUO Jianxin, HAN Jian. DEPDC1 is up-regulated in uterine corpus endometrial cancer [J]. Basic & Clinical Medicine, 2023, 43(9): 1399-1407.
[2]	TANG Yijun, WANG Wenlong, LI Jiangli, YANG Huan, SUN Jing. LncRNA RP11-686D22.10 is related with the survival of breast cancer patients, affects the proliferation, invasion of breast cancer cell lines [J]. Basic & Clinical Medicine, 2023, 43(7): 1023-1029.
[3]	JIN Xiaoxia, LU Xiaoyun, LIU Yushan, LIANG Lina. Expression and clinical significance of SIRT2 in urothelial bladder cancer and its impact on cancer cell proliferation, invasion and migration [J]. Basic & Clinical Medicine, 2023, 43(7): 1090-1096.
[4]	ZENG Yankun, HONG Xiaoying, CHEN Qinglin. Down-regulation of BECN1 inhibits the proliferation, invasion and migration of human leukemia cell line THP-1 [J]. Basic & Clinical Medicine, 2023, 43(7): 1104-1109.
[5]	ZHANG Hailing, YANG Yu, ZHOU Qianqian, WANG Yuanjin, WANG Ting. Neutrophil NETs treated with microcystin-LR promote migration of colorectal cancer cell [J]. Basic & Clinical Medicine, 2023, 43(6): 967-973.
[6]	LENG Haina, ZHANG Yan, WANG Xiaodong, ZHANG Xueyou, LI Hongli. miR-767-5p inhibits the invasion of ovarian cancer cell lines by regulating the expression of TBL1XR1 protein [J]. Basic & Clinical Medicine, 2023, 43(3): 408-414.
[7]	WANG Wenlong, TANG Yijun, WANG Qingbing, CHEN Ke, CHENG Jiqiang. Knockdown of lncRNA RP11-626G11.3 inhibits proliferation and migration of human renal carcinoma cell lines through regulating miR-532-3p [J]. Basic & Clinical Medicine, 2023, 43(10): 1498-1504.
[8]	HE Jing, LI Yan, WANG Yan-feng, BAO Hui. Up-expression of FABP4 promotes the proliferation and migration of endometrial cancer cell line HEC-1-A [J]. Basic & Clinical Medicine, 2022, 42(9): 1356-1361.
[9]	ZHANG Xiao-lei, LIU Jing, LI Chao-ping. Circ_0032821 is involved in sorafenib's inhibition of the proliferation, migration and invasion of breast cancer cell line T47D [J]. Basic & Clinical Medicine, 2022, 42(9): 1350-1354.
[10]	WANG Juan, ZHANG Xiao-yan, ZHU Ai-hua, YU Hong-bo, FAN Xin-dan, TANG Chun-hui, YAO Xiu-fang. High expression of Ku70 promotes proliferation of ovarian cancer cell lines and is associated with a poor prognosis for patients [J]. Basic & Clinical Medicine, 2022, 42(9): 1391-1399.
[11]	SHEN Yong-hua, WANG Jun-feng, CHENG Ze-xing, FENG Juan-juan. Esculin inhibits the proliferation of human nasopharyngeal carcinoma cell line HNE-3 [J]. Basic & Clinical Medicine, 2022, 42(8): 1237-1242.
[12]	LIU Lei, LI Shi-bao, ZHANG Hao-liang. Lnc-SLC2A12-10:1 silencing inhibits the proliferation, migration and invasion of gastric cancer cell line AGS [J]. Basic & Clinical Medicine, 2022, 42(7): 1071-1076.
[13]	ZHONG Ming, YU Xiu-yi, GUO Wei-xi, FANG Zheng. Ophiopogonin B inhibits proliferation and migration of human esophageal squamous cell carcinoma cell line EC9706 [J]. Basic & Clinical Medicine, 2022, 42(7): 1053-1059.
[14]	BAI Bing, ZHANG Hai-fang, YANG Qing-liang, QIN Yue, ZHOU Chen-long, SONG Ge, WANG Ying. Down-regulation of lncRNA RHPN1-AS1 inhibits proliferation and migration of human bladder cancer cell line T24 [J]. Basic & Clinical Medicine, 2022, 42(6): 940-944.
[15]	DU Xue-mei, ZHANG Yun-mei, ZHOU Wen-ting, LYU Hong. miR-655-3p targeting KIF20A inhibits migration and invasion of lung adenocarcinoma cell line A549 [J]. Basic & Clinical Medicine, 2022, 42(4): 599-606.